Back
Bioanalysis of labile compounds – Part 1
A significant number of compounds of pharmaceutical interest contain linkages susceptible to cleavage by blood-borne enzymes (predominantly esterases). In many cases, this lability is a desirable feature of the compound concerned: in the case of prodrugs it is used to enhance delivery of an active principle; alternatively, limited systemic persistence may be a desirable aspect of the therapeutic use (e.g. local anaesthetics). However, this desirable therapeutic characteristic can lead to extreme problems when compounds of this type are to be determined in blood, plasma or serum.
To read the full text of this article you need to be registered with us. If you have already done so you can Login Now, or alternatively please Register your details with us.
Back
Printer Friendly  |   Sitemap © Unilabs Bioanalytical Solutions 2010 - 2017  |   Privacy Policy  |   Website Disclaimer  |   Website Credits